专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明公开

EP0835078A1 FLUOROCHEMICAL LIQUID AUGMENTED CRYOSURGERY 失效
标题翻译：使用FLUOR化学液体药品的FOR刀治疗的生产
公开(公告)号：EP0835078A1
公开(公告)日：1998-04-15
申请号：EP96920456.0
申请日：1996-05-21
申请人： Temple University of the Commonwealth System of Higher Education
发明人： STERN, Robert, G. , SHAFFER, Thomas, H. , WOLFSON, Marla, R.
IPC分类号： A61B18 , A61B19
CPC分类号： A61B18/0218 , A61B18/02 , A61B2018/00101 , A61B2018/0022 , A61B2018/0212 , A61B2090/378 , A61B2090/3925 , A61B2090/3933 , A61B2218/002
摘要： This invention is a method for cryogenic treatment of a lesion (20) which comprises the steps of delivering a fluoro-chemical liquid to the lesion (20), placing at least one cryoprobe (26) into the lesion (20), and circulating a cryogenic fluid causing an ice ball (30) to form in a vicinity around the cryoprobe (26), wherein the ice ball (30) obliterates at least a portion of the lesion (20). The fluoro-chemical liquid is utilized to augment the cryosurgical procedure and is perfused or injected into and/or around the lesion site prior and/or during the application of a cryprobe (26) to the site. In one embodiment of the invention, the fluoro-chemical liquid acts as a contrast agent to enhance real time medical imaging of the lesion area and modifies the environment in and around the lesion area. In another embodiment of the invention, the fluoro-chemical liquid augments cryosurgical procedures by controlling the size and shape of ice balls (30) formed during the cryosurgical procedures. In this embodiment, a fluoro-chemical liquid with a properly chosen thermal conductivity and freezing point is utilized. Depending on the thermal properties chosen, the liquid either augments freezing of the target area and/or promotes thermal conduction to freeze larger areas, or limits the freezing of the target area and reduces thermal conduction. In an non-cryoprobe embodiment, the liquid is cooled to a temperature below the freezing point of the biological tissue. The cooled liquid is then infused into or around the cystic lesion to produce ablation.

92. 发明公开

EP0821582A2 CONTROLLED RELEASE TABLET 失效
标题翻译：与控释片
公开(公告)号：EP0821582A2
公开(公告)日：1998-02-04
申请号：EP96908487.0
申请日：1996-02-28
申请人： TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
发明人： KIM, Cherng-Ju
IPC分类号： A61K9 , A61K31 , A61K47
CPC分类号： A61K9/2072 , A61K9/2031 , A61K9/2054
摘要： A controlled release tablet including a pharmaceutical agent and an excipient. The excipient includes at least about 50 % of a water swellable polymer and a lubricant. The water swellable polymer is chosen such that the swelling rate of the polymer is equal to the dissolution rate of the swollen polymer. The excipient may also include such other ingredients as diluents, fillers, binders and other pharmacologically inactive compounds. The polymer is chosen with the pharmaceutical agent in mind such that the tablet will be fully dissolved at the same time that the last of the pharmaceutical agent is released.

93. 发明公开

EP0775896A2 Improved container for liquid crystal cumulative dosimeter 失效
标题翻译： VerbesserterBehälterfürkumulativeFlüssigkeitskristalldosimeter
公开(公告)号：EP0775896A2
公开(公告)日：1997-05-28
申请号：EP97100850.3
申请日：1991-12-19
申请人： TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
发明人： Labes, M. Mortimer
IPC分类号： G01K11/00
CPC分类号： G01K3/04 , G01K11/165 , Y10S252/962
摘要： A container (10, 10A, 10B, 10C, 10D, 10E) for a liquid crystal cumulative dosimeter including a resilient outer body (12, 12A, 12B, 12C, 12D, 12E) sealed to confine a first liquid crystal composition constituent (14, 14A, 14B, 14C, 14D, 14E) and a second liquid crystal composition constituent (16, 16A, 16B, 16C, 16D, 16E) and having at least one transparent section (20) to permit observation of the color of the confined composition, and a barrier (30) contained completely within and physically unattached to the outer body for separating the first constituent from the second constituent, whereby disruption of the barrier allows the first constituent to mix with the second constituent. The barrier is formed by using air bubbles. Methods of manufacturing the various containers shown and processes of using those containers are also disclosed.
摘要翻译：一种用于液晶累积剂量计的容器（10,10A，10B，10C，10D，10E），其包括密封以限制第一液晶组成物（14）的弹性外体（12,12A，12B，12C，12D，12E），14A，14B，14C，14D，14E）和第二液晶组合物成分（16,16A，16B，16C，16D，16E），并且具有至少一个透明部分（20），以便观察被限制的颜色组合物和隔离物（30）完全包含在外部并且物理上不附着于外部主体，用于将第一成分与第二成分分离，由此破坏屏障允许第一成分与第二成分混合。屏障通过使用气泡形成。还公开了制造所示各种容器的方法以及使用这些容器的方法。

94. 发明公开

EP0716856A2 Therapeutic uses of 2',5'-oligoadenylate derivatives 失效
标题翻译： Therapeutische Anwendungen von 2'，5'-Oligoadenylat-Derivaten
公开(公告)号：EP0716856A2
公开(公告)日：1996-06-19
申请号：EP96101815.7
申请日：1989-05-24
申请人： Temple University of the Commonwealth System of Higher Education
发明人： Suhadolnik, Robert J. , Pfleiderer, Wolfgang
IPC分类号： A61K31/70 , C07H21/00
CPC分类号： A61K31/70 , A61K31/7088 , A61K31/7115 , A61K31/712 , A61K31/7125 , A61K47/554 , C07H21/00 , C07H23/00
摘要： Synthetic analogs of 2',5'-oligoadenylate wherein the aglycon, ribosyl moiety and/or terminal nucleoside have been modified are effective therapeutic agents, particularly against HIV infection. The analogs are utilized in compositions for the treatment of disorders characterized by 2-5A pathway defects.
摘要翻译：其中糖苷配基，核糖基部分和/或末端核苷已被修饰的2'，5'-寡腺苷酸的合成类似物是有效的治疗剂，特别是抗HIV感染。类似物用于治疗以2-5A途径缺陷为特征的疾病的组合物中。

95. 发明授权

EP0286239B1 Production and purification of a protein fused to a binding protein 失效
标题翻译：制备和纯化，其稠合到结合蛋白的蛋白质的
公开(公告)号：EP0286239B1
公开(公告)日：1996-03-13
申请号：EP88302039.8
申请日：1988-03-09
申请人： NEW ENGLAND BIOLABS, INC. , Temple University of the Commonwealth System of Higher Education
发明人： Guan, Chudi , Inouye, Hiroshi
IPC分类号： C12N15/00 , C12N11/00 , C12P21/02
CPC分类号： C12N15/52 , C07K2319/24 , C07K2319/50 , C12N15/62

96. 发明公开

EP0667778A1 TREATMENT OF MELANOMA WITH ANTISENSE OLIGONUCLEOTIDES TO C-MYB PROTO-ONCOGENE 失效
标题翻译：治疗反义寡C-MYB原癌基因恶性黑色素瘤。
公开(公告)号：EP0667778A1
公开(公告)日：1995-08-23
申请号：EP92924379.0
申请日：1992-11-12
申请人： Temple University of the Commonwealth System of Higher Education , University of Pennsylvania
发明人： GEWIRTZ, Alan, M. , CALABRETTA, Bruno
IPC分类号： A61K31 , A61K48 , C07H21 , C12N15 , A61K38
CPC分类号： A61K31/70 , A61K38/00 , C07H21/00 , C12N15/1135 , C12N2310/3125 , C12N2310/315
摘要： Melanoma is treated by administering oligonucleotides having a nucleotide sequence complementary to at least a portion of the mRNA transcript of the human c-myb gene. These 'antisense' oligonucleotides are hybridizable to the c-myb mRNA transcript.

97. 发明公开

EP0650378A1 TREATMENT OF PHYSIOLOGICAL CONDITIONS WITH DEGASSED PERFLUOROCARBON LIQUID 失效
标题翻译：处理条件与生理学脱气全氟化碳液体。
公开(公告)号：EP0650378A1
公开(公告)日：1995-05-03
申请号：EP93917159.0
申请日：1993-07-14
申请人： Temple University of the Commonwealth System of Higher Education
发明人： SHAFFER, Thomas, H. , WOLFSON, Marla, R.
IPC分类号： A61M31 , A61K31 , A61M1 , A61M3 , A61F7 , A61M5
CPC分类号： A61M1/00 , A61F7/00 , A61M3/00 , A61M5/44 , A61M2202/02 , A61M2202/04 , A61M2202/0476 , A61M2202/0014 , A61M2202/0007
摘要： This invention pertains to the use of a degassed perfluorocarbon ('PFC') liquid as a method of removing gas emboli from parts of a patient's body cava. Moreover, the invention can be used as a method of imaging parts of a patient's body cava. Furthermore, the invention can also be used as a way of delivering biological agents to parts of a patient's body cava which contain or are surrounded by gas emboli and/or which are to be imaged. In this invention, a degassed PFC liquid is delivered to a region within the patient's body cava which contains gas emboli and/or which is to be imaged. If gas emboli are present, the degassed liquid is permitted to absorb at least a portion of the emboli. Thereafter, the emboli-containing liquid is removed from the patient or is used as an imaging agent. If gas emboli are not present, the site is imaged before the degassed liquid reaches atmospheric equilibrium. Thereafter, the liquid is removed from the patient. Moreover, by mixing a biological agent with the degassed PFC liquid, the mixture can be used as a way of topically treating parts within a patient's body cava. Furthermore, by regulating the temperature of the degassed liquid, it can also be used as a way of hypo- or hyperthermically treating the patient.

98. 发明授权

EP0341904B1 Method for predicting the effectiveness of antineoplastic therapy in individual patients 失效
标题翻译：一种用于预测在antineoplastichen个别患者治疗的有效性的方法。
公开(公告)号：EP0341904B1
公开(公告)日：1995-03-29
申请号：EP89304494.1
申请日：1989-05-04
申请人： Temple University of the Commonwealth System of Higher Education
发明人： Gewirtz, Alan M. , Calabretta, Bruno
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6897 , C12Q1/6886 , C12Q2600/106 , Y10S436/813

99. 发明公开

EP0630249A1 DUAL ACTION 2',5'-OLIGOADENYLATE ANTIVIRAL DERIVATIVES AND USES THEREOF 失效
标题翻译： DUAL ACTION 2'，5'-OLIGOADYYLATE ANTIVIRAL DERIVATIVES AND USES THEREOF
公开(公告)号：EP0630249A1
公开(公告)日：1994-12-28
申请号：EP93906054.0
申请日：1993-02-18
申请人： Temple University of the Commonwealth System of Higher Education
发明人： SUHADOLNIK, Robert J. , PFLEIDERER, Wolfgang
IPC分类号： C07H21 , A61K31 , A61P31 , C07J43 , C07J51 , C08B37
CPC分类号： A61K31/70 , A61K47/549 , A61K47/551 , A61K47/554 , A61K47/557 , C07H21/00 , C07J43/003 , C07J51/00
摘要： L'invention se rapporte à une infection virale que l'on inhibe chez les mammifères en leur administrant des dérivés 2-5A métaboliquement stables de 2'-5'-oligoadénylate non toxique qui ont un double effet thérapeutique. Les composés activent l'endoribonucléase RNase L intracellulaire latente, 2-5A-dépendante, et inhibent également l'action des ADN polymérases virales. L'invention concerne également des conjugués des dérivés 2-5A utilisés dans les traitements thérapeutiques.
摘要翻译：本发明涉及通过施用具有双重治疗效果的无毒性2'-5'-寡聚腺苷酸的代谢上稳定的2-5A衍生物而在哺乳动物中受到抑制的病毒感染。该化合物激活2-5A依赖性潜伏细胞内细胞内RNase L，并且还抑制病毒DNA聚合酶的作用。本发明还涉及用于治疗性处理的2-5A衍生物的缀合物。

100. 发明授权

EP0210029B1 Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same 失效
标题翻译：单克隆抗体对人体血浆前血管舒缓素及其制备方法和用途。
公开(公告)号：EP0210029B1
公开(公告)日：1994-06-01
申请号：EP86305373.2
申请日：1986-07-14
申请人： Temple University of the Commonwealth System of Higher Education
发明人： Veloso, Dulce C. , Colman, Robert W.
IPC分类号： C07K15/00 , C12P21/00 , C12N15/00 , C12N5/00 , G01N33/573 , G01N33/577
CPC分类号： C07K16/40 , A61K38/00

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式